Overview
- The Justice Department order dated April 22 placed FDA‑approved cannabis drugs and state‑licensed medical marijuana in Schedule III and created a fast federal registration path for those operators.
- The policy is narrow and does not legalize marijuana, so recreational or unlicensed products remain in Schedule I under stricter federal controls.
- Scientists say the shift will cut red tape for studies and let labs test the same flower, vapes and edibles patients use, opening the door to larger randomized clinical trials.
- Companies expect relief from IRS rule 280E on medical sales and see a path to banking access, though Treasury, IRS and other agencies still need to spell out how and when changes take effect.
- The DEA scheduled a June 29 hearing on broader rescheduling, and attorneys caution that immigration consequences and DOT drug‑testing rules largely remain in place until further action.